Dianthus Therapeutics, Inc.
DNTH · NASDAQ
Company research
Dianthus Therapeutics, Inc. (Nasdaq: DNTH) is a clinical-stage biotechnology company headquartered in New York City, dedicated to developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company's lead product candidate, claseprubart (DNTH103), is a highly potent and selective human monoclonal antibody engineered with extended half-life that targets the active form of the C1s complement protein, currently being evaluated in Phase 2/3 clinical trials for generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN). In addition, Dianthus is advancing DNTH212, a bifunctional fusion protein designed to reduce Type 1 interferon production while simultaneously suppressing B cell function, targeting diseases such as Sjögren's disease and systemic lupus erythematosus (SLE). Founded in 2019 and led by CEO Marino Garcia, the company has raised over $1.6 billion in capital to date, including a $719 million public offering in March 2026, positioning it as a well-funded, late-stage biotech competitor in the high-value neurology and immunology market.
Research reports
Comprehensive AI-driven equity research report that frames DNTH as a highly capitalized clinical-stage biotech with asymmetric upside from its complement-focused pipeline, led by claseprubart and DNTH212, supported by an estimated \$1.1–1.2B cash balance, runway into 2030, and probability-weighted 5‑year price targets implying substantial upside. It also details trial designs and TAM for gMG, CIDP and MMN, lays out rNPV-based valuation scenarios, and highlights binary Phase 3 efficacy, safety, payer, and dilution risks as key thesis drivers.
Zacks Investment Research · June 16, 2026DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?Short-form equity analysis explaining DNTH’s roughly 89% six‑month share price gain as driven by claseprubart’s multi‑indication opportunity (CIDP, gMG, MMN), positive Phase 2 MaGic data, Orphan Drug designation in gMG, and pipeline expansion via DNTH212. The report emphasizes DNTH’s strengthened balance sheet after a \$719M equity offering that lifted cash to about \$1.2B and notes a Zacks Rank #3 (Hold), stressing that regulatory and pipeline setbacks remain material risks for this still pre‑revenue biotech.
Simply Wall St · June 9, 2026Dianthus Therapeutics Future GrowthQuantitative fundamental report summarizing consensus forecasts that DNTH’s revenue is expected to grow about 77.6% per year while earnings and EPS growth remain negative, with detailed tables of projected revenue, earnings, free cash flow and cash from operations through 2028. It highlights strong forecast revenue growth versus the broader US market, good analyst coverage from 18 firms, and a positive long‑term growth narrative, but also notes that DNTH is forecast to remain unprofitable over at least the next three years and that future ROE is uncertain.
Finterra (syndicated On Chronicle Journal / WorkBoat) · March 12, 2026Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 BreakthroughNarrative deep‑dive that re‑positions DNTH as a high‑conviction late‑stage complement inhibitor platform after early responder threshold success in the Phase 3 CAPTIVATE CIDP trial, detailing the company’s reverse‑merger history, “pipeline‑in‑a‑product” business model, and leadership credentials of CEO Marino Garcia and Chairman Lonnie Moulder. It explains claseprubart’s selective C1s mechanism, half‑life extension and low‑volume auto‑injector dosing, compares DNTH’s profile against Argenx, Sanofi and Immunovant, discusses cash runway (guided into 2028+), and outlines catalysts such as MMN data, gMG Phase 3 initiation and potential M&A alongside execution, commercialization, pricing and regulatory risks.